StockMarketWire.com - Biomarker company Oxford BioDynamics booked a deeper annual loss amid a rise in expenses, including staff costs.

Pre-tax losses for the year through September amounted to £3.4m, compared to losses of £2.4m on-year.

Revenue fell to £0.9m, down from £1.2m.

The company had cash and term deposits of £15.5m at the end of September, down from £18.3m a year earlier.

Chief executive Christian Hoyer Millar said the company had delivered several important achievements during the year, including signing collaboration agreements for its flaghsip EpiSwitch product.

'We believe there is significant potential for EpiSwitch biomarkers to benefit a range of diseases, but we have been particularly pleased with the progress we have announced in immuno-oncology ,' Hoyer Millar said.

'We have continued to gain traction in this important, growing market demonstrating the value we add to the healthcare system.'


At 9:42am: [LON:OBD] Oxford Biodynamics Plc share price was -7.5p at 103.5p



Story provided by StockMarketWire.com